{
    "id": 4971,
    "name": "myelofibrosis",
    "source": "DOID",
    "definition": "A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue. [url:http\\://en.wikipedia.org/wiki/Myelofibrosis]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "5737"
    ],
    "termId": "DOID:4971",
    "evidence": [
        {
            "id": 1099,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 838,
                    "pubMedId": 21725052,
                    "title": "Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725052"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1100,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).",
            "molecularProfile": {
                "id": 590,
                "profileName": "MPL W515K"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 838,
                    "pubMedId": 21725052,
                    "title": "Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725052"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4413,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial that supported FDA approval, treatment with Jakafi (ruxolitinib) resulted in a decrease in spleen volume of greater than or equal to 35% in 41.9% of patients with intermediate or high-risk myelofibrosis, compared to 0.7% of patients treated with the placebo (PMID: 22474318).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4521,
                    "pubMedId": 22474318,
                    "title": "Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22474318"
                },
                {
                    "id": 15607,
                    "pubMedId": null,
                    "title": "Jakafi (ruxolitinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202192"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5814,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 treatment reduced disease burden in MPL W515L transduced mouse models of myelofibrosis (PMID: 23748344).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 839,
                    "pubMedId": 23748344,
                    "title": "AKT is a therapeutic target in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23748344"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6062,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CHZ868 demonstrated efficacy in a mouse model of MPL W515L induced myelofibrosis (PMID: 26175413).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5260,
                    "pubMedId": 26175413,
                    "title": "CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26175413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10435,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (JAKARTA) that supported FDA approval, Inrebic (fedratinib) demonstrated both clinical benefits and toxicity in myelofibrosis patients, resulting in symptom response rates at week 24 of 36% (33/91), 34% (31/91), and 7% (6/85) in the Fedratinib (SAR302503) 400 mg, 500 mg, and placebo groups, respectively (P<.001) (PMID: 26181658; NCT01437787).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8448,
                    "pubMedId": 26181658,
                    "title": "Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26181658"
                },
                {
                    "id": 16008,
                    "pubMedId": null,
                    "title": "Inrebic (fedratinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212327"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11400,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with myelofibrosis and positive for EPHA3 showed clinical improvement when treated with KB004 (PMID: 27736729).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9290,
                    "pubMedId": 27736729,
                    "title": "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27736729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13575,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with XL019 demonstrated clinical activity in 23% (7/30) of myelofibrosis patients, including 27% (6/22) of patients with JAK2 V617F and 13% (1/8) with wild-type JAK2, and resulted in responses in 10% (3/30) of patients, however, resulted in neurotoxicity and the trial was discontinued (PMID: 24374145; NCT00595829).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2778,
                "therapyName": "XL019",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11188,
                    "pubMedId": 24374145,
                    "title": "Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24374145"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13577,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two myelofibrosis patients harboring CALR L367fs (reported as L367fs*46 for patient 1 and L367fs*48 for patient 2) and wild-type JAK2 demonstrated a greater than 50% reduction in spleen size following treatment with Inrebic (fedratinib) (PMID: 24645956).",
            "molecularProfile": {
                "id": 21266,
                "profileName": "CALR L367fs"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3954,
                    "pubMedId": 24645956,
                    "title": "JAK inhibitor in CALR-mutant myelofibrosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24645956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13696,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "JAK2 V617F is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 591,
                "profileName": "JAK2 V617F"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13697,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "MPL W515L is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13700,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "MPL W515K is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 590,
                "profileName": "MPL W515K"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13701,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "CALR mutations are associated with improved survival when compared to JAK2 mutations or concurrent wild-type CALR, MPL, and JAK2 in patients with primary myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 23414,
                "profileName": "CALR mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13705,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of the CALR type 1 mutation, L367fs, or a type 1-like mutation is associated with improved overall survival compared to a CALR type 2 (K385fs) or CALR type 2-like mutation and JAK2 V617F in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 21266,
                "profileName": "CALR L367fs"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13707,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of concurrent wild-type JAK2, MPL, and CALR in myelofibrosis patients is associated with inferior leukemia-free survival compared to patients with JAK2 and/or CALR mutations, and is associated with inferior overall survival when compared to patients with CALR mutations (NCCN.org).",
            "molecularProfile": {
                "id": 29392,
                "profileName": "CALR wild-type JAK2 wild-type MPL wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13708,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "ASXL1 mutations are associated with inferior overall survival and leukemia-free survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 3486,
                "profileName": "ASXL1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13709,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "EZH2 mutations are associated with inferior overall survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13710,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "IDH1 mutations are associated with inferior leukemia-free survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 1781,
                "profileName": "IDH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13711,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "IDH2 mutations are associated with inferior leukemia-free survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 5912,
                "profileName": "IDH2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13712,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "SRSF2 mutations are associated with inferior overall survival and leukemia-free survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 22843,
                "profileName": "SRSF2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13713,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of a CALR mutation combined with wild-type ASXL1 is associated with longer survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 29393,
                "profileName": "ASXL1 wild-type CALR mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13714,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of an ASXL1 mutation combined with wild-type CALR is associated with shorter survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 29394,
                "profileName": "ASXL1 mut CALR wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13715,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of a CALR mutation combined with an ASXL1 mutation is associated with intermediate survival in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 29395,
                "profileName": "ASXL1 mut CALR mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17852,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Keytruda (pembrolizumab) treatment resulted in suppression of PDCD1 (PD-1)-positive T cells and expansion of clonal T cell populations that may target C-terminal mutant Calr in a patient with myelofibrosis harboring CALR L367Tfs*46 (PMID: 31266769; NCT02897765).",
            "molecularProfile": {
                "id": 32831,
                "profileName": "CALR L367Tfs*46 PDCD1 pos"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15822,
                    "pubMedId": 31266769,
                    "title": "Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31266769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19084,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "U2AF1 Q157 mutations are associated with inferior overall survival compared to U2AF1 S34 mutations or wild-type U2AF1 in patients with primary myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 29344,
                "profileName": "U2AF1 Q157X"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01398462",
            "title": "Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3081,
                    "therapyName": "CWP232291",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02098161",
            "title": "LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3641,
                    "therapyName": "LCL161",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02158858",
            "title": "A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8583,
                    "therapyName": "CPI-0610 + Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 2033,
                    "therapyName": "CPI-0610",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02251821",
            "title": "JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1843,
                    "therapyName": "Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 1845,
                    "therapyName": "Mycophenolate mofetil",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 2006,
                    "therapyName": "Pacritinib",
                    "synonyms": null
                },
                {
                    "id": 823,
                    "therapyName": "Momelotinib",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1639,
                    "therapyName": "Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02421354",
            "title": "Study of Nivolumab in Patients With Myelofibrosis",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02440685",
            "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7391,
                    "therapyName": "ASN002",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02493530",
            "title": "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7984,
                    "therapyName": "Ruxolitinib + Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02528877",
            "title": "Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2237,
                    "therapyName": "Fludarabine + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 3181,
                    "therapyName": "Ruxolitinib + Sirolimus + Tacrolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02530034",
            "title": "Hu8F4 in Treating Patients With Advanced Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9617,
                    "therapyName": "Hu8F4",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02530619",
            "title": "Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02564536",
            "title": "Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3177,
                    "therapyName": "Decitabine + Pacritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02718300",
            "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4224,
                    "therapyName": "Parsaclisib + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02966353",
            "title": "Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03042689",
            "title": "Study of Regorafenib in Patients With Advanced Myeloid Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03065400",
            "title": "PD-1 Inhibition in Advanced Myeloproliferative Neoplasms",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03136185",
            "title": "IMG-7289 in Patients With Myelofibrosis",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7194,
                    "therapyName": "IMG-7289",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03144687",
            "title": "A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7986,
                    "therapyName": "Itacitinib + Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 2406,
                    "therapyName": "Itacitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03165734",
            "title": "A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 1750,
                    "therapyName": "Hydroxyurea",
                    "synonyms": null
                },
                {
                    "id": 2006,
                    "therapyName": "Pacritinib",
                    "synonyms": null
                },
                {
                    "id": 1475,
                    "therapyName": "Thalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03289910",
            "title": "Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5341,
                    "therapyName": "Carboplatin + Topotecan + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 7710,
                    "therapyName": "Carboplatin + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03326310",
            "title": "Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6467,
                    "therapyName": "Azacitidine + Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03373877",
            "title": "Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7990,
                    "therapyName": "PU-H71 + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03592576",
            "title": "Expanded Access to Navitoclax",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 825,
                    "therapyName": "Navitoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03627403",
            "title": "Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03662126",
            "title": "KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1452,
                    "therapyName": "KRT-232",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03755518",
            "title": "An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 911,
                    "therapyName": "Fedratinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03862157",
            "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7993,
                    "therapyName": "Azacitidine + MLN4924 + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03886831",
            "title": "A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9735,
                    "therapyName": "PRT543",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03895112",
            "title": "MPN-RC 118 AVID200 in Myelofibrosis",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7613,
                    "therapyName": "AVID200",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03912064",
            "title": "A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03935555",
            "title": "Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1162,
                    "therapyName": "PU-H71",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04089449",
            "title": "A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9227,
                    "therapyName": "PRT811",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04173494",
            "title": "A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9187,
                    "therapyName": "Danazol",
                    "synonyms": null
                },
                {
                    "id": 823,
                    "therapyName": "Momelotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04176198",
            "title": "A Study of Oral TP-3654 in Patients With Myelofibrosis",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3672,
                    "therapyName": "TP-3654",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04217356",
            "title": "Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis",
            "phase": "Phase 0",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9783,
                    "therapyName": "Hydroxyurea + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04279847",
            "title": "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 4319,
                    "therapyName": "INCB057643",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04281498",
            "title": "Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9426,
                    "therapyName": "Enasidenib + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04282187",
            "title": "Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9427,
                    "therapyName": "Decitabine + Fedratinib",
                    "synonyms": null
                },
                {
                    "id": 1735,
                    "therapyName": "Decitabine + Ruxolitinib",
                    "synonyms": null
                }
            ]
        }
    ]
}